U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07648823) titled 'Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma' on June 10.
Brief Summary: The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer. [177Lu]Lu-XT771 is designed to specifically target and deliver beta radiation directly to tumor cells that overexpress carbonic anhydrase IX and XII (CA IX and CA XII).
This early-phase, investigator-initiated trial will enroll a small group of approximately 3-5 patients, each receiving...